In the early days, postoperative management of DBS was usually the responsibility of the neurologist/movement disorder specialist together with the functional neurosurgeon who performed the surgery, because postoperative management included both medical and surgical aspects. In recent years, with more and more patients receiving surgical treatment, it is imperative to incorporate post-operative management into the full management of the functional neurosurgery center. This has placed greater demands on the functional neurosurgeon specializing in Parkinson’s disease. As a functional neurosurgeon, you must do the following: (1) Surgery and postoperative program control: the surgeon knows the most about the patient’s condition, intraoperative tests, surgical procedures, and postoperative rehabilitation before and after surgery, and the surgeon can shorten the program control time and evaluate the effect more accurately by turning on the machine and program control for the first time. Post-operative program control: The micro-destructive effect of post-operative electrode implantation allows patients to show significant improvement in motor symptoms even without stimulation 3-5 days or even half a month after surgery, so the first program control is usually started after 3-4 weeks. The procedure is usually performed in the “off” state of the drug, including the selection of the best electrode contact for stimulation, evaluation of the stimulation effect, evaluation of side effects, definition of the treatment window and setting of the stimulation parameters (during the “off” and “on” periods of the drug, respectively). (off” and “on” periods, respectively). (2) Drug adjustment: Usually performed during the “on” phase of stimulation, which is not identical for different patients and different stimulation sites (GPi or STN). In patients with STN DBS, levodopa dosage can often be reduced, and in a few young patients it can even be stopped completely, with an average reduction of 50%, whereas in patients with GPi DBS it can rarely be reduced. Levodopa drugs should be reduced gradually, and abrupt discontinuation should be avoided in patients on long-term, high-dose levodopa therapy because of the possibility of motor inability crisis. In addition, attention must be paid to non-motor symptoms such as apathy (lack of pleasure, lack of willpower) and even depression that occur during the drug reduction process. (3) Post-operative patient education: Post-operative patient control needs to be repeated several times over the course of several months to a year in order to optimize stimulation and perfect synergistic treatment with medication. Unlike destructive surgery, patients need to avoid being near magnetic fields in their daily lives due to the DBS implantation device in the patient’s body, and learn to apply a magnet switch or patient programmable control to allow for a quick turn on in case of a stimulation period shut down due to proximity to high magnetic fields. In addition, the DBS device may cause infection, rejection or skin necrosis in some patients, so call back to the surgeon as soon as the wound becomes red, swollen or broken.